2-((2-(4-Iodo-2,5-dimethoxyphenyl)ethylamino)methyl)phenol (25I-NBOH) and 2-(((2-(4-chloro-2,5-dimethoxyphenyl)ethyl)amino)methyl)phenol (25C-NBOH) induce adverse effects on the cardiovascular system.
K. S. Yoon, Hye Jin Cha, S. Choi, Jin-Moo Lee
Toxicology Letters November 1, 2021 DOI: 10.1016/j.toxlet.2021.11.016 (opens in new tab) via Semantic Scholar
Summary
AI-generated from the abstractTwo new psychoactive substances, 25I-NBOH and 25C-NBOH, abused as recreational hallucinogens, were evaluated for cardiotoxicity. In cell and animal tests, both compounds decreased viability of rat heart cells and prolonged QT and RR intervals in rat electrocardiography, indicating potential heart rhythm disturbances. 25I-NBOH reduced PAK1 protein expression in heart cells and inhibited potassium channels in a hERG assay, while 25C-NBOH did not affect PAK1 expression. Neither substance altered the pumping function or heart rate of isolated rat hearts. The findings suggest both substances may pose cardiovascular risks, with further research needed on the role of PAK1.
Study at a glance
| Characteristics | Experimental study Peer reviewed |
|---|---|
| Population | H9c2 rat cardiomyocytes and primary rat cardiomyocytes; male rats for ECG; isolated rat hearts for Langendorff test |
| Interventions | 25I-NBOH 25C-NBOH |
| Keywords | Medicine Chemistry |
| Key finding | Both 25I-NBOH and 25C-NBOH decreased cardiomyocyte viability and prolonged QT and RR intervals in rats, indicating potential cardiotoxicity. |
Abstract
Two new psychoactive substances (NPSs) classified as phenethylamines, namely 2-((2-(4-Iodo-2,5-dimethoxyphenyl)ethylamino)methyl)phenol (25I-NBOH) and 2-(((2-(4-chloro-2,5-dimethoxyphenyl)ethyl)amino)methyl)phenol (25C-NBOH), are being abused by people seeking recreational hallucinogens. These NPSs may cause serious health problems as their adverse effects are not known in most cases. Therefore, in the present study, we evaluated the cardiotoxicity of 25I-NBOH and 25C-NBOH using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay, rat electrocardiography (ECG), Langendorff test, and human ether-a-go-go-related gene (hERG) assay. Furthermore, we analyzed the expression levels of p21 CDC42/RAC1-activated kinase 1 (PAK1), which is known to play various roles in the cardiovascular system. In the MTT assay, treatment with 25I-NBOH or 25C-NBOH dramatically decreased viability of H9c2 cardiomyocytes. Meanwhile, these two compounds significantly increased QT intervals and RR intervals in the rat ECG measurement. 25I-NBOH down-regulated the PAK1 protein expression in rat primary cardiomyocytes as well as H9c2 cells. However, 25C-NBOH had no effect on the PAK1 expression in H9c2 cells. In an in-depth study, 25I-NBOH inhibited potassium channels in the hERG assay, but in ex vivo test, the substance did not affect the left ventricular developed pressure (LVDP) and heart rate of the isolated rat hearts. Taken together, these results suggest that both 25I-NBOH and 25C-NBOH may have adverse cardiovascular effect. Further investigation would be needed to determine which factors mainly influence the relationship between PAK1 expression and cardiotoxicity.